WallStSmart

ATAI Life Sciences BV (ATAI)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ATAI Life Sciences BV generates 503% more annual revenue ($4.47M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. ATAI earns a higher WallStSmart Score of 28/100 (F).

ATAI

Avoid

28

out of 100

Grade: F

Growth: 7.3Profit: 2.5Value: 6.7Quality: 7.0
Piotroski: 4/9Altman Z: -10.64

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ATAIUndervalued (+62.8%)

Margin of Safety

+62.8%

Fair Value

$10.66

Current Price

$7.35

$3.31 discount

UndervaluedFair: $10.66Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ATAI2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
137.0%10/10

Revenue surging 137.0% year-over-year

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

ATAI4 concerns · Avg: 2.8/10
Price/BookValuation
15.3x4/10

Trading at 15.3x book value

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-378.0%2/10

ROE of -378.0% — below average capital efficiency

EPS GrowthGrowth
-96.8%2/10

Earnings declined 96.8%

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
16.8x4/10

Trading at 16.8x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : ATAI

The strongest argument for ATAI centers on Revenue Growth, Debt/Equity. Revenue growth of 137.0% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : ATAI

The primary concerns for ATAI are Price/Book, Profit Margin, Return on Equity.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

ATAI profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

ATAI carries more volatility with a beta of 1.55 — expect wider price swings.

ATAI is growing revenue faster at 137.0% — sustainability is the question.

ATAI generates stronger free cash flow (-35M), providing more financial flexibility.

Bottom Line

ATAI scores higher overall (28/100 vs 24/100) and 137.0% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ATAI Life Sciences BV

HEALTHCARE · BIOTECHNOLOGY · USA

ATAI Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?